NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow Biosciences, the biotechnology subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), is pleased to announce that its joint venture target, Amarantus BioSciences (OTCBB: AMBS) has secured over $1.1 million in funding through two separate transactions. In addition to strengthening the company’s balance sheet, financing will go toward funding Amarantus’ ground-breaking new treatments and diagnostics for neurological diseases including Parkinson’s, Traumatic Brain Injury (TBI), Alzheimer’s and more.
